HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Foshan Haitian Flavouring & Food Company (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Muyuan Foods - The Hog King in China Has Greater Potential and Resilience

Sichuan Kelun-Biotech Biopharm (6990.HK) Placement - Thoughts The Pipeline and Valuation Outlook

Pre-IPO Jiangsu Hengrui Medicine H Share Listing (PHIP Updates) - Some Points Worth the Attention

Chagee Holdings - Debut Is the Peak, and Then It Wanes?

Pre-IPO Green Tea Group - Thoughts on IPO Pricing and Valuation Outlook

Pre-IPO Green Tea Group (PHIP Updates) - Some Points Worth the Attention

Equity Capital Markets

<ul>
<li>GASTROClear's clinical application may be limited by doctors' lack of sufficient trust/recognition. GASTROClear could mainly be commercialized in the non-clinical market in China first. However, the competition is more intense.</li>
<li>The dual pressure of lack of medical insurance reimbursement and higher pricing may lead to lower-than-expected market penetration.It’s not easy for Mirxes’ revenue to return to the level of 2021.</li>
<li>Short-Term valuation depends on market sentiment, but in long term, it still depends on the commercialization performance and the improvement of cash flow. The IPO pricing is expensive.</li>
</ul>


GASTROClear's clinical application may be limited by doctors' lack of sufficient trust/recognition. GASTROClear could mainly be commercialized in the non-clinical market in China first. However, the competition is more intense.
The dual pressure of lack of medical insurance reimbursement and higher pricing may lead to lower-than-expected market penetration.It’s not easy for Mirxes’ revenue to return to the level of 2021.
Short-Term valuation depends on market sentiment, but in long term, it still depends on the commercialization performance and the improvement of cash flow. The IPO pricing is expensive.


Pre-IPO Mirxes Holding (PHIP Updates) - Some Points Worth the Attention